4.7 Article

Rat brain guanosine binding site: Biological studies and pseudo-receptor construction

Journal

BIOORGANIC & MEDICINAL CHEMISTRY
Volume 11, Issue 24, Pages 5417-5425

Publisher

PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/j.bmc.2003.09.043

Keywords

-

Ask authors/readers for more resources

Rat brain guanosine binding sites were studied by (i) a pharmacological approach to confirm the hypothesis of the existence of specific G-coupled receptors for guanosine (1) and, for the first time, delineate a structure-activity relationship for a series of guanosine derivatives; (ii) a molecular modelling approach to design a pseudo-receptor construction. GTP and its non-hydrolysable analogue Gpp[NH]p decreased [H-3]-guanosine binding to rat brain membranes. Gpp[NH]p 30 and 100 muM induced a dose-dependent decrease in [H-3]-guanosine affinity and PTX pretreatment of rat brain membranes caused a 50% reduction in binding. In slices from rat brain cortex, guanosine induced a dose-dependent increase in intracellular cAMP. This increase is specific for guanosine, since neither the pretreatment with adenosine deaminase nor the A(1) and A(2) adenosine receptor antagonists were able to modify the guano sine-induced cAMP accumulation. The structure activity relationship showed that the potency order of the best substances able to displace 50 nM [H-3]-guanosine was guanosine (1) = 6-thioguanosine (3) > 8-bromoguanosine (4) > mosine (10) > 7-methylguanosine (6) = 3'-deoxyguanosine (9) > 2'-deoxyguanosine (8) = guanine (11) = 6-thioguanine (12) >> N-2-methylguanosine (5). The competition studies confirmed that [H-3]-guanosinosite was distinct from the well characterized ATP and adenosine binding sites. The present results are rationalized in terms of a putative pseudo-receptor construct which includes all the relevant physicochemical interaction between guanosine analogues and their putative binding sites. This construct will be useful for the in silico screening of compound libraries in search for new potent and structurally diverse pharmacological tools. (C) 2003 Elsevier Ltd. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available